A Phase 2 interventional study of MEDI3506 and Placebo in Diabetic Kidney Disease, sponsored by AstraZeneca. Completed at 97 sites in 7 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2024-07-10.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.
Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 12th largest by enrollment of the 120 interventional ones that give a count, is one of 8 that started in 2019, is one of 54 in phase 2, and was the 103rd registered.
543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–80
Medical University of South Carolina · Sites in United States
Ages 18–75
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–75 · Healthy volunteers
Seattle Children's Hospital · Sites in United States
Ages 14–40
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 101 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 61 · Phase 3 16 · Phase 4 10
First in 1981; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 609 is above the median of 78 across 388 interventional studies indexed under Diabetic Nephropathies.
Median enrollment 79 across the 120 interventional studies, 175 across the 31 observational. Of the 115 that completed or were terminated, 46 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
70 of 153 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Diabetic Nephropathies — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetic Nephropathies with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05759468Brigham and Women's HospitalNAD Augmentation in Diabetes Kidney Disease | 2026-11-30 |
| NCT07022418Medical University of South CarolinaFormoterol in Diabetes | 2026-12 |
| NCT04802395Renalytix AI, Inc.Real World Evidence Clinical Utility Study of KidneyIntelX | 2026-12-01 |
| NCT05507892University of Colorado, DenverRenal Mechanism of SGLT2 Inhibition | 2026-12-15 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
Add all 12 to your calendar (.ics) → With an account.
Among the 153 studies in Diabetic Nephropathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease
This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, PK, and immunogenicity of MEDI3506 on top of standard of care, including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and dapagliflozin in adult subjects with diabetic kidney disease, defined as subjects with type 2 diabetes mellitus (T2DM) and an estimated glomerular filtration rate (eGFR) of 25-75 mL/min/1.73 m2 with a UACR in the range of 100-3000 mg/g, who meet all eligibility criteria. Approximately 565 subjects, among multiple countries will be randomized to MEDI3506 dose 1, 2, 3 or dose 4, or placebo during a treatment period of 24 weeks. All subjects will receive Dapagliflozin daily, as administered orally from Day 85 to Day 168. The primary objective is to evaluate the effect of MEDI3506 on albuminuria in subjects with DKD. Secondary objectives include evaluating safety, PK and the incidence of ADA during the treatment period.
Key Inclusion Criteria
Diabetic kidney disease DKD defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
Drug: MEDI3506 · Drug: Dapagliflozin
MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
Drug: MEDI3506 · Drug: Dapagliflozin
MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
Drug: MEDI3506 · Drug: Dapagliflozin
MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
Drug: MEDI3506 · Drug: Dapagliflozin
Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
Drug: Placebo · Drug: Dapagliflozin
Dose 1, Dose 2, Dose 3, Dose 4
Placebo
Dapagliflozin 10 mg
Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
Time frame: From baseline to Day 169
Percent Change From Baseline to Day 85 (Week 12) in UACR - Per Protocol Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
Time frame: From baseline to Day 85
Percent Change From Day 85 (Week 12) to Day 169 (Week 24) in UACR - Per Protocol Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from Day 85 up to Day 169.
Time frame: From Day 85 to Day 169
Proportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Per Protocol Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.
Time frame: Baseline and Day 169
Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
Time frame: From baseline to Day 169
Percent Change From Baseline to Day 85 (Week 12) in UACR - Full Analysis Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
Time frame: From baseline to Day 85
Proportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Full Analysis Population
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.
Time frame: Baseline and Day 169
Immunogenicity of MEDI3506 - PK Analysis Population
ADA prevalence: number of participants ADA positive (ADA+) at baseline and/or post-baseline. Treatment-induced ADA+: ADA not detected or missing at baseline and at least one post-baseline ADA+. Treatment-boosted ADA+: ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point. Treatment-emergent ADA+ (TE-ADA + or ADA incidence): Treatment-induced ADA+ OR and Treatment-boosted ADA+.
Time frame: Day 1 to Day 230
Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population
Participants were tested for COVID-19 during the course of the study. Descriptive analysis of asymptomatic participants tested positive for COVID-19 during the study.
Time frame: Day 1 to Day 230
Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events Among COVID-19 Positive Participants - Safety Analysis Population
For participants tested positive for COVID-19 during the intervention and follow-up periods, this analysis provides: * the number and proportion of subjects with any treatment-emergent adverse event * the number and proportion of subjects with any treatment-emergent serious adverse event
Time frame: Day 1 to Day 230
Plasma Concentration of MEDI3506 - PK Analysis Population
MEDI3506/Tozorakimab serum concentrations were measured using a validated assay method.
Time frame: Day 1, Day 29, Day 85 and Day 169
| Milestone | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Started | 147 | 96 | 101 | 95 | 160 |
| Completed | 99 | 70 | 70 | 68 | 120 |
| Not completed | 48 | 26 | 31 | 27 | 40 |
| Withdrew: Death | 1 | 1 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 13 | 6 | 5 | 4 | 9 |
| Withdrew: Not able to transition to phase 2b | 8 | 0 | 10 | 0 | 6 |
| Withdrew: Enrolled in site with gcp breach | 6 | 1 | 2 | 2 | 4 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 2 |
| Withdrew: (crf) | 16 | 15 | 12 | 17 | 17 |
| Withdrew: Due to covid-19 pandemic | 1 | 0 | 1 | 0 | 0 |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
| Percentage change from baseline | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population | -14.82 (-27.05 to -0.53) | -17.25 (-30.69 to -1.19) | -31.45 (-42.54 to -18.21) | -29.70 (-41.61 to -15.37) | -20.96 (-31.32 to -9.04) |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
| Percentage change from baseline | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline to Day 85 (Week 12) in UACR - Per Protocol Population | 21.60 (7.39 to 37.70) | 5.77 (-8.00 to 21.60) | -9.66 (-21.46 to 3.91) | -0.53 (-14.10 to 15.18) | 2.69 (-8.32 to 15.01) |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from Day 85 up to Day 169.
| Percentage change from baseline | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Percent Change From Day 85 (Week 12) to Day 169 (Week 24) in UACR - Per Protocol Population | -23.26 (-32.77 to -12.39) | -17.69 (-29.17 to -4.36) | -20.87 (-31.70 to -8.32) | -25.87 (-36.49 to -13.47) | -19.21 (-28.28 to -9) |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.
| Participants | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| UACR reduction > 30% | 43 | 34 | 28 | 38 | 59 |
| UACR reduction > 40% | 33 | 23 | 23 | 29 | 45 |
| UACR reduction > 50% | 22 | 17 | 19 | 23 | 35 |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
| Percentage change from baseline | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population | -15.82 (-27.33 to -2.49) | -13.77 (-27.25 to 2.20) | -28.98 (-40.20 to -15.64) | -30.94 (-41.93 to -17.86) | -21.19 (-31.29 to -9.59) |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.
| Percentage change from baseline | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Percent Change From Baseline to Day 85 (Week 12) in UACR - Full Analysis Population | 16.86 (3.59 to 31.83) | 7.59 (-6.16 to 23.35) | -7.23 (-19.29 to 6.63) | -5.03 (-17.55 to 9.39) | 1.35 (-9.52 to 13.53) |
UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.
| Participants | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| UACR reduction > 30% | 49 | 36 | 28 | 41 | 62 |
| UACR reduction > 40% | 37 | 25 | 23 | 32 | 48 |
| UACR reduction > 50% | 26 | 18 | 19 | 26 | 38 |
ADA prevalence: number of participants ADA positive (ADA+) at baseline and/or post-baseline. Treatment-induced ADA+: ADA not detected or missing at baseline and at least one post-baseline ADA+. Treatment-boosted ADA+: ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point. Treatment-emergent ADA+ (TE-ADA + or ADA incidence): Treatment-induced ADA+ OR and Treatment-boosted ADA+.
| Participants | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Treatment-induced ADA+ | 1 | 6 | 10 | 12 | 12 |
| Treatment-boosted ADA+ | 0 | 1 | 0 | 0 | 2 |
| Treatment-emergent ADA+ (Treatment-induced ADA+ or Treatment-boosted ADA+) | 1 | 7 | 10 | 12 | 14 |
MEDI3506/Tozorakimab serum concentrations were measured using a validated assay method.
| ng/mL | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Day 1 | 0.01063 ± 418.9 | 0.005232 ± 38.16 | 0.005261 ± 33.33 | 0.005111 ± 12.30 | 0.005443 ± 79.38 |
| Day 29 | 0.01983 ± 533.3 | 0.2185 ± 110.3 | 0.4454 ± 144.4 | 0.7036 ± 119.7 | 1.884 ± 64.34 |
| Day 85 | 0.02898 ± 711.3 | 0.2754 ± 155.6 | 0.4701 ± 140.1 | 0.9547 ± 103.2 | 2.326 ± 80.10 |
| Day 169 | 0.02435 ± 919.4 | 0.2495 ± 132.2 | 0.4231 ± 188.4 | 0.7027 ± 200.1 | 2.402 ± 91.04 |
Participants were tested for COVID-19 during the course of the study. Descriptive analysis of asymptomatic participants tested positive for COVID-19 during the study.
| Participants | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population | 79 | 54 | 50 | 53 | 70 |
For participants tested positive for COVID-19 during the intervention and follow-up periods, this analysis provides: * the number and proportion of subjects with any treatment-emergent adverse event * the number and proportion of subjects with any treatment-emergent serious adverse event
| Participants | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Any adverse event | 47 | 35 | 23 | 30 | 40 |
| Any serious adverse event | 11 | 9 | 1 | 6 | 3 |
Collected over Day 1 to Day 230. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/133 (0.8%) | 15/133 (11.3%) | 62/133 (46.6%) |
| MEDI3506 30 mg | 1/95 (1.1%) | 14/95 (14.7%) | 55/95 (57.9%) |
| MEDI3506 60 mg | 1/89 (1.1%) | 5/89 (5.6%) | 39/89 (43.8%) |
| MEDI3506 120 mg | 1/93 (1.1%) | 12/93 (12.9%) | 48/93 (51.6%) |
| MEDI3506 300 mg | 1/148 (0.7%) | 11/148 (7.4%) | 74/148 (50%) |
| Event | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/133 | 0/95 | 0/89 | 2/93 | 0/148 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/133 | 2/95 | 0/89 | 0/93 | 0/148 |
| Acute kidney injuryRenal and urinary disorders | 2/133 | 1/95 | 0/89 | 1/93 | 1/148 |
| Covid-19Infections and infestations | 1/133 | 0/95 | 1/89 | 0/93 | 1/148 |
| Septic shockInfections and infestations | 0/133 | 0/95 | 1/89 | 1/93 | 0/148 |
| Cardio-respiratory arrestCardiac disorders | 0/133 | 0/95 | 1/89 | 0/93 | 0/148 |
| HypervolaemiaMetabolism and nutrition disorders | 0/133 | 0/95 | 1/89 | 0/93 | 0/148 |
| HypovolaemiaMetabolism and nutrition disorders | 0/133 | 0/95 | 1/89 | 0/93 | 0/148 |
| Intervertebral disc degenerationMusculoskeletal and connective tissue disorders | 0/133 | 0/95 | 1/89 | 0/93 | 0/148 |
| FaecalomaGastrointestinal disorders | 0/133 | 0/95 | 1/89 | 0/93 | 0/148 |
| Event | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg |
|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/133 | 8/95 | 0/89 | 2/93 | 2/148 |
| HypertensionVascular disorders | 3/133 | 6/95 | 1/89 | 7/93 | 7/148 |
| HyperkalaemiaMetabolism and nutrition disorders | 5/133 | 4/95 | 5/89 | 3/93 | 9/148 |
| Back painMusculoskeletal and connective tissue disorders | 4/133 | 5/95 | 2/89 | 3/93 | 1/148 |
| Covid-19Infections and infestations | 6/133 | 3/95 | 3/89 | 4/93 | 5/148 |
| Urinary tract infectionInfections and infestations | 5/133 | 3/95 | 4/89 | 0/93 | 3/148 |
| DiarrhoeaGastrointestinal disorders | 2/133 | 1/95 | 4/89 | 3/93 | 4/148 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/133 | 4/95 | 0/89 | 0/93 | 4/148 |
| Oedema peripheralGeneral disorders | 4/133 | 4/95 | 1/89 | 2/93 | 6/148 |
| PyrexiaGeneral disorders | 2/133 | 4/95 | 0/89 | 1/93 | 2/148 |
| Age, Continuous(years) | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 66.7 ± 9.7 | 67.1 ± 9.8 | 67.2 ± 10.1 | 66.6 ± 9.7 | 65.9 ± 10.1 | 66.6 ± 9.9 |
| Sex: Female, Male(Participants) | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg | Total |
|---|---|---|---|---|---|---|
| Sex — Female | 46 | 33 | 23 | 24 | 43 | 169 |
| Sex — Male | 87 | 62 | 66 | 69 | 105 | 389 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg | Total |
|---|---|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 61 | 62 | 31 | 53 | 81 | 288 |
| Ethnicity — Not Hispanic or Latino | 72 | 33 | 58 | 40 | 67 | 270 |
| Ethnicity — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg | Total |
|---|---|---|---|---|---|---|
| Race — American Indian or Alaska Native | 2 | 5 | 0 | 1 | 4 | 12 |
| Race — Asian | 29 | 15 | 24 | 17 | 29 | 114 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 1 | 3 | 1 | 2 | 8 |
| Race — Black or African American | 16 | 6 | 9 | 4 | 13 | 48 |
| Race — White | 81 | 68 | 53 | 66 | 96 | 364 |
| Race — More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Race — Unknown or Not Reported | 3 | 0 | 0 | 4 | 4 | 11 |
| Region of Enrollment(Participants) | Placebo | MEDI3506 30 mg | MEDI3506 60 mg | MEDI3506 120 mg | MEDI3506 300 mg | Total |
|---|---|---|---|---|---|---|
| Argentina | 20 | 28 | 12 | 28 | 25 | 113 |
| Canada | 4 | 2 | 7 | 2 | 6 | 21 |
| Chile | 13 | 12 | 2 | 9 | 17 | 53 |
| Japan | 20 | 11 | 15 | 11 | 18 | 75 |
| Korea, Republic of; South Korea | 4 | 3 | 2 | 3 | 3 | 15 |
| Peru | 0 | 3 | 0 | 0 | 4 | 7 |
| United States | 72 | 36 | 51 | 40 | 75 | 274 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2019 to primary completion in May 2023, 41 months.
Results were first posted in Jul 2024, 1 year 1 month after primary completion.
Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 41 months is above that.
Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tozorakimab